Asthma clinical trial
Asthmatics needed for Waikato clinical trial
Genentech Inc. (a member of the Roche group) are developing an antibody that blocks activities of a protein that is released from airway cells in response to viral infections, allergens, irritants and other triggers of asthma disease flare or exacerbations. The antibody is given by small injections under the skin every 4 weeks for 12 months.
To participate in the study you must:
- be an adult (18 years – 75 years) with moderate to severe asthma who are not well controlled on their current inhalers
- have had at least an asthma exacerbation in the previous 12 months (needed to take prednisone)
- not be pregnant or breast feeding
- have a BMI <38
- not be a smoker
The screening period will determine if you are eligible to participate in the study. This will involve breathing tests, questionnaires and the ability to complete an electronic diary. You would be required to attend appointments in the morning and some appointments may take up to 3 hours. You will not be paid for your participation, however reasonable travel costs will be reimbursed.
For further information please email: Christine.Tuffery@waikatodhb.health.nz
Read more about our Respiratory research team